These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31999942)

  • 1. β-adrenoreceptors and the risk of Parkinson's disease.
    Hopfner F; Höglinger GU; Kuhlenbäumer G; Pottegård A; Wod M; Christensen K; Tanner CM; Deuschl G
    Lancet Neurol; 2020 Mar; 19(3):247-254. PubMed ID: 31999942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β2-adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Gronich N; Abernethy DR; Auriel E; Lavi I; Rennert G; Saliba W
    Mov Disord; 2018 Sep; 33(9):1465-1471. PubMed ID: 30311974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between developing Parkinson's disease and β-Adrenoceptor acting agents use: A systematic review and meta-analysis.
    Saengphatrachai W; Praditukrit K; Owattanapanich W; Pitakpatapee Y; Srivanitchapoom P
    J Neurol Sci; 2021 Nov; 430():120009. PubMed ID: 34598055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.
    Hopfner F; Wod M; Höglinger GU; Blaabjerg M; Rösler TW; Kuhlenbäumer G; Christensen K; Deuschl G; Pottegård A
    Neurology; 2019 Jul; 93(2):e135-e142. PubMed ID: 31127070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.
    McCaffrey PM; Riddell JG; Shanks RG
    Br J Clin Pharmacol; 1987 Nov; 24(5):571-80. PubMed ID: 2893634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case-Control Study.
    de Germay S; Conte C; Rascol O; Montastruc JL; Lapeyre-Mestre M
    CNS Drugs; 2020 Jul; 34(7):763-772. PubMed ID: 32500347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chronic application of propranolol on beta-adrenergic signal transduction in heart ventricles from myopathic BIO TO2 and control hamsters.
    Witte K; Schnecko A; Hauth D; Wirzius S; Lemmer B
    Br J Pharmacol; 1998 Nov; 125(5):1033-41. PubMed ID: 9846642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists.
    Emilien G; Maloteaux JM
    Eur J Clin Pharmacol; 1998 Feb; 53(6):389-404. PubMed ID: 9551698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease.
    Ellison KE; Gandhi G
    Drugs; 2005; 65(6):787-97. PubMed ID: 15819591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β2-adrenoreceptor medications and risk of Parkinson disease.
    Searles Nielsen S; Gross A; Camacho-Soto A; Willis AW; Racette BA
    Ann Neurol; 2018 Nov; 84(5):683-693. PubMed ID: 30225948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
    Baker JG
    Br J Pharmacol; 2005 Feb; 144(3):317-22. PubMed ID: 15655528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term application of metoprolol and propranolol in a rat model of smoking.
    Zhou Y; Xu M; Zhang Y; Guo Y; Zhang Y; He B
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):708-15. PubMed ID: 24837395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype-selective modulation of human beta 1- and beta 2-adrenoceptor function by beta-adrenoceptor agonists and antagonists.
    Brodde OE; Daul A; Michel MC
    Clin Physiol Biochem; 1990; 8 Suppl 2():11-7. PubMed ID: 1982757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between β2-Adrenoreceptor Medications and Risk of Parkinson's Disease: A Meta-Analysis.
    Chen CL; Wang SY; Chen TC; Chuang CS
    Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684044
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
    van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA
    Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta2-Adrenoceptor Agonists in Parkinson's Disease and Other Synucleinopathies.
    Magistrelli L; Comi C
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):74-81. PubMed ID: 30617750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro.
    Yamanishi T; Chapple CR; Yasuda K; Yoshida K; Chess-Williams R
    Neurourol Urodyn; 2003; 22(4):338-42. PubMed ID: 12808710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences between the third cardiac beta-adrenoceptor and the colonic beta 3-adrenoceptor in the rat.
    Kaumann AJ; Molenaar P
    Br J Pharmacol; 1996 Aug; 118(8):2085-98. PubMed ID: 8864547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noradrenaline, beta-adrenoceptor mediated vasorelaxation and nitric oxide in large and small pulmonary arteries of the rat.
    Priest RM; Hucks D; Ward JP
    Br J Pharmacol; 1997 Dec; 122(7):1375-84. PubMed ID: 9421285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in cardiovascular responsiveness to dopexamine and beta 1- and beta 2-adrenoceptor function after the chronic treatment of beta-adrenoceptor antagonists and agonists in anaesthetized dogs.
    Chang DH; Einstein R
    J Auton Pharmacol; 1996 Oct; 16(5):269-79. PubMed ID: 9023671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.